Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: Comparison with clinical response and patients' outcome

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 2, 2006, Pages 421-431

  Goteri, G ^a   Olivieri, A ^a,b   Ranaldi, R ^a   Lucesole, M ^a,b   Filosa, A ^a   Capretti, R ^a   Pieramici, T ^a   Leoni, P ^a,b   Rubini, C ^a   Fabris, G ^a   Lo Muzio, Lorenzo ^a,c  

^a Institute of Pathology   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Bone marrow; Immunohistochemistry; PCR; Rituximab; Small B cell lymphomas

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLONAL VARIATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DRUG TOLERANCE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HAIRY CELL LEUKEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; LYMPHOPLASMACYTIC LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR DYNAMICS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; T LYMPHOCYTE;

EID: 33746833616     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900218     Document Type: Article

References (26)

1. Reff M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, N. Hanna and D.R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
2. Demidem A., T. Lam, S. Alas, K. Hariharan, N. Hanna and B. Bonavida. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177.
3. Shan D., J.A. Ledbetter and O.W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644.
4. Douglas V.K., L.I. Gordon, C.L. Goolsby, C.A. White and L.C. Peterson. 1999. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma. Am. J. Clin. Pathol. 112:844.
5. Foran J.M., A.J. Norton, I.N. Micallef, D.C. Taussig, J.A. Amess, A.Z. Rohatiner and T.A. Lister. 2001. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br. J. Haematol. 114: 881.
6. Kinoshita T., H. Nagai, T. Murate and H. Saito. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J. Clin. Oncol. 16:3916.
7. Davis T.A., D.K. Czerwinski and R. Levy. 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5:611.
8. Schmitz K., W. Brugger, B. Weiss, E. Kaiserling and L. Kanz. 1999. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br. J. Haematol. 106:571.
9. Venugopal P., W.T. Leslie, T. O'Brien and S.A. Gregory. 1999. CD20-negative relapse after (131)I-anti-CD20 therapy. J. Clin. Oncol. 17:3692.
10. Swerdlow S.H., J.A. Habeshaw, L.J. Murray and A.G. Stansfeld. 1989. T cells in follicular centroblastic/centrocytic (cleaved follicular centre cell) lymphomas at diagnosis, relapse and transformation. Hematol. Oncol. 7:355.
11. Jaffee E.S., N.L. Harris, H. Stein and J.W. Vardiman. 2001. World Health Organization Classification of Tumors. In Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press Lyon France, p. 1.
12. Cheson B.D., S.J. Horning, B. Coiffier, M.A. Shipp, R.I. Fisher, J.M. Connors, T.A. Lister, J. Vose, A. Grillo-Lopez, A. Hagenbeek, F. Cabanillas, D. Klippensten, W. Hiddemann, R. Castellino, N.L. Harris, J.O. Armitage, W. Carter, R. Hoppe and G.P. Canellos. 1999. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17:1244.
13. Diss T.C., L. Pan, H. Peng, A.C. Wotherspoon and P.G. Isaacson. 1994. Sources of DNA for detecting B cell monoclonality using PCR. J. Clin. Pathol. 47:493.
14. Ghielmini M., S.F. Schmitz, S.B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M.F. Fey, D.C. Betticher, G. Martinelli, F. Peccatori, U. Hess, E. Zucca, R. Stupp, T. Kovacsovics, C. Helg, A. Lohri, M. Bargetzi, D. Vorobiof and T. Cerny. 2004. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103:4416.
15. Foran J.M., D. Cunningham, B. Coiffier, P. Solal-Celigny, F. Reyes, M. Ghielmini, P.W. Johnson, C. Gisselbrecht, M. Bradburn, J. Matthews and T.A. Lister. 2000. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann. Oncol. 11 (S1):117.
16. Dvoretsky P., G.S. Wood, R. Levy and R.A. Warnke. 1982. T-lymphocyte subsets in follicular lymphomas compared with those in non-neoplastic lymph nodes and tonsils. Hum. Pathol. 13:618.
17. Grillo-Lopez A.J. 2000. Rituximab: an insider's historical perspective. Semin. Oncol. 27:9.
18. Howard O.M., J.G. Gribben, D.S. Neuberg, M. Grossbard, C. Poor, M.J. Janicek and M.A. Shipp. 2002. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20:1288.
19. Byrd J.C., K. Rai, B.L. Peterson, F.R. Appelbaum, V.A. Morrison, J.E. Kolitz, L. Shepherd, J.D. Hines, C.A. Schiffer and R.A. Larson. 2005. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49.
20. Huh Y.O., M.J. Keating, H.L. Saffer, I. Jilani, S. Lerner and M. Albitar. 2001. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 116:437.
21. Taylor R.P., A.D. Kennedy, P.V. Beum, M.A. Lindorfer, D.J. DiLillo, C.E. Hess, J.J. Densmore and M.E. Williams. 2003. Treatment of Chronic Lymphocytic Leukemia (CLL) patients with Rituximab (RTX) depletes complement (C) and induces selective loss of B cell-bound CD20/RTX immune complexes: evidence for removal of these immune complexes by the mononuclear phagocytic. Blood 102:110a.
22. Czuczman M.S., J.J. Testa, D. Brombos and F.J. Hernandez-Ilizaliturri. 2003. Pathways involved in the emergence of resistance to Rituximab in non-Hodgkins lymphoma (NHL) cell lines. Blood 102: 103a.
23. Davis R.E., T.A. Longacre and P.J. Cornbleet. 1994. Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings, and differential diagnosis. Am. J. Clin. Pathol. 102:202.
24. Vandersteenhoven A.M., J.E. Williams and M.J. Borowitz. 1993. Marrow B-cell precursors are increased in lymphomas or systemic diseases associated with B-cell dysfunction. Am. J. Clin. Pathol. 100:60.
25. Farahat N., D. Lens, A. Zomas, R. Morilla, E. Matutes and D. Catovsky. 1995. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br. J. Haematol. 91: 640.
26. Rambaldi A., M. Lazzari, C. Manzoni, et al. 2002. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856.